It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
DNA polymerase theta (Polθ)-mediated end-joining (TMEJ) repairs DNA double-strand breaks and confers resistance to genotoxic agents. How Polθ is regulated at the molecular level to exert TMEJ remains poorly characterized. We find that Polθ interacts with and is PARylated by PARP1 in a HPF1-independent manner. PARP1 recruits Polθ to the vicinity of DNA damage via PARylation dependent liquid demixing, however, PARylated Polθ cannot perform TMEJ due to its inability to bind DNA. PARG-mediated de-PARylation of Polθ reactivates its DNA binding and end-joining activities. Consistent with this, PARG is essential for TMEJ and the temporal recruitment of PARG to DNA damage corresponds with TMEJ activation and dissipation of PARP1 and PAR. In conclusion, we show a two-step spatiotemporal mechanism of TMEJ regulation. First, PARP1 PARylates Polθ and facilitates its recruitment to DNA damage sites in an inactivated state. PARG subsequently activates TMEJ by removing repressive PAR marks on Polθ.
Here the authors reveal a two-step spatiotemporal regulation of (Polθ)-mediated end-joining (TMEJ). First, PARP1 PARylates Polθ and facilitates its recruitment to the vicinity of DNA damage sites in an inactivated state. PARG subsequently activates TMEJ by removing repressive PAR marks on Polθ.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Temple University, Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Philadelphia, USA (GRID:grid.264727.2) (ISNI:0000 0001 2248 3398)
2 Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, USA (GRID:grid.415231.0) (ISNI:0000 0004 0577 7855)
3 The Wistar Institute, Proteomics and Metabolomics Facility, Philadelphia, USA (GRID:grid.251075.4) (ISNI:0000 0001 1956 6678)
4 Temple University, Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Philadelphia, USA (GRID:grid.264727.2) (ISNI:0000 0001 2248 3398); Temple University, Department of Cancer and Cellular Biology, Lewis Katz School of Medicine, Philadelphia, USA (GRID:grid.264727.2) (ISNI:0000 0001 2248 3398); Fox Chase Cancer Center, Nuclear Dynamics and Cancer Program, Philadelphia, USA (GRID:grid.249335.a) (ISNI:0000 0001 2218 7820)